Results from a Phase IIb 24-week clinical trial show that Atacicect is safe and may benefit people with high levels of disease activity.
$3.8 million committed by the Lupus Foundation of America to support first-of-its-kind research.
Dr. Rosalind Ramsey-Goldman and Dr. José Crispín are recognized by the Lupus Foundation of America for their achievements in lupus research.
A Lupus Foundation of America study finds almost 50% of adults with lupus are misdiagnosed at the start of their journey.
New population-based analyses measure incidence and prevalence of lupus among these fast growing U.S. populations.
Benlysta SC is the first self-injection lupus treatment that can administered at home once per week.
Patient-reported data collected in the Registry will accelerate the development of new treatments and help to unravel the mysteries of lupus.